Skip to main content
. 2015 Dec 24;2(4):ofv155. doi: 10.1093/ofid/ofv155

Figure 5.

Figure 5.

The effects of an endothelin receptor type B (ETBR) blocker, BQ788, on endothelial cells proliferation, migration, vasculogenecity, and leukocyte recruitment. (A) Cell proliferation assay by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) was performed in human umbilical vein cells (HUVECs) untreated or treated with BQ788 at the indicated time points after treatment. Optical density was read at 590 nm with reference wavelength at 670 nm. (B) Light microscopic images (×4) of the wound healing assay were taken at different times after the “scratch” of HUVEC monolayers untreated or treated with BQ788. (C) Light microscopic images (×4) of tube formation by HUVECs untreated or treated with BQ788. (D) Light microscopic images of flow adhesion assay in cells stimulated with tumor necrosis factor-α (TNFα) and untreated or treated with BQ788 (left panel). The number of adherent cells was quantified for all the conditions (right panel). Values are mean ± standard deviation; P < .05 was considered to be statistically significant; *P = .01–.05; **P = .001–.01; ***P < .001).